BELMONITOR COV-2
LIVE

Serial Number

79305894

Owner

Pharmact Holding AG

Attorney

Brian P. Gregg

Filing Date

Dec 22, 2020

Add to watchlist:

No watchlists yet
View on USPTO

BELMONITOR COV-2 Trademark

Serial Number: 79305894 • Registration: 6720755

BELMONITOR COV-2 is a trademark filed by Pharmact Holding AG on December 22, 2020. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus). The application is currently registered and active.

Owner Contact Info

Pharmact Holding AG (6 trademarks)

Zugerstraße 76B

Entity Type: 84

Rainer Böhnke (5 trademarks)

Imbrosweg 23

Entity Type: 01

Trademark Details

Filing Date

December 22, 2020

Registration Date

May 24, 2022

Published for Opposition

February 22, 2022

Goods & Services

Reagents for medical use; diagnostic chemical reagents for medical use; clinical medical reagents; clinical diagnostic reagents for medical purposes; enzymes for medical purposes with all of the foregoing for use in testing and diagnosing Sars-Cov-2 exposure; medical preparations and chemicals for pharmaceutical use, namely, for use in the treatment and disagnosis of SARS,COV-2 or Covid-19; pharmaceutical preparations in strip form for the treatment of Covid-19; pharmaceutical preparations for the prevention of disorders of the endocrine system that may be affected by Covid-19; chemical preparations for testing blood for medical purposes to determine Sars-Cov-2 or Covid-19 exposure; chemical preparations for medical purposes, namely, for the treatment of Covid-19; chemico-pharmaceutical preparations for the treatment of Covid-19; pharmaceutical preparations for the prevention of diseases of the metabolic system, in particular, Sars-Cov-2; in-vitro reagents for medical diagnostic purposes to determine exposure to Sars-Cov-2; chemical preparations for pharmaceutical purposes, namely, for treatment of Covid-19; medical diagnostic test strips for testing for Covid-19 viral infection; diagnostic agents for medical use and diagnostic reagents for medical use in testing for Sars-Cov-2 exposure; medicated mouth spray for treating Covid-19 viral infections; pharmaceutical preparations for the prevention of disorders of the metabolic system related to Sars-Cov-2 exposure; pharmaceutical preparations for the treatment of Covid-19 viral infections; chemical preparations for use in DNA analysis for medical purposes related to diagnosing and treating Sars-Cov-2; biological reagents for medical diagnostic use for medical purposes related to diagnosing and treating Sars-Cov-2; diagnostic chemical reagents for medical use related to diagnosing and treating Sars-Cov-2

Genetic testing apparatus for medical purposes for diagnosing exposure to Sars-Cov-2; chromatogram analyzers for medical use; patient monitoring sensors and alarms; chromatographic instruments for medical use; tools for medical diagnostics, namely, medical ultrasound apparatus, spirometers, electromagnetic medical diagnostic imaging apparatus, medical instruments for examining women's reproductive organs, medical instruments for use in performing biopsies; chromatographic apparatus for medical use; physical analyzers for medical use, namely, hematology analyzers for medical diagnostic uses, body composition analyzers for medical purposes, skin moisture analyzers for medical purposes, analyzers for the analysis of body fluids; medical diagnostic saliva pads; immunoadsorption columns for medical diagnostic use; chromatographic columns for medical use; apparatus for blood monitoring for medical use; spittoons for medical purposes; all of the foregoing for use in diagnosing or treating Sars-Cov-2 infections

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Nov 7, 2022 FINO
GENERIC MADRID TRANSACTION SENT TO IB
Sep 14, 2022 XXSS
GENERIC MADRID TRANSACTION CREATED
Sep 14, 2022 XXCR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Aug 24, 2022 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
May 24, 2022 NRCC
REGISTERED-PRINCIPAL REGISTER
May 24, 2022 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 22, 2022 NPUB
PUBLISHED FOR OPPOSITION
Feb 22, 2022 PUBO
NOTIFICATION PROCESSED BY IB
Feb 20, 2022 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Feb 2, 2022 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Feb 2, 2022 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 2, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 14, 2022 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 11, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 10, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 10, 2022 TROA
REFUSAL PROCESSED BY IB
Aug 1, 2021 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jul 14, 2021 RFCS
REFUSAL PROCESSED BY MPU
Jul 14, 2021 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jul 13, 2021 RFCR
NON-FINAL ACTION WRITTEN
Jul 12, 2021 CNRT
ASSIGNED TO EXAMINER
Jul 7, 2021 DOCK
ASSIGNED TO EXAMINER
Jun 28, 2021 DOCK
ASSIGNED TO EXAMINER
Jun 18, 2021 DOCK
APPLICATION FILING RECEIPT MAILED
Mar 12, 2021 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 8, 2021 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Mar 4, 2021 REPR